ARVN Stock Analysis: Arvinas | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 541m USD | 12M Return: 10.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.93M
Qual. Beats: 0
Rev. Trend: 42.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut, founded in 2013 and listed on NASDAQ since September 2018. The company focuses on developing therapies based on its proprietary PROTAC (proteolysis targeting chimera) platform, a modality that harnesses the bodys ubiquitin-proteasome system to selectively degrade disease-causing proteins, rather than merely inhibiting their activity as traditional small molecules do.
Arvinas clinical pipeline spans oncology and neurodegenerative diseases, including ARV-102 (LRRK2) for Parkinsons disease and progressive supranuclear palsy, ARV-806 (KRAS G12D) for pancreatic, colorectal, and non-small cell lung cancers, ARV-393 (BCL6) for relapsed/refractory non-Hodgkin lymphoma, ARV-027 (polyglutamine-expanded androgen receptor) for muscle disorders, and vepdegestrant (estrogen receptor) for ER+/HER2- breast cancer. The company is also advancing bavdegalutamide (ARV-110) and luxdegalutamide (ARV-766) for metastatic castration-resistant prostate cancer. As a clinical-stage biotech without approved products, Arvinas relies on collaborations with major pharmaceutical partners, including Pfizer, Genentech/Roche, Bayer, and Carrick Therapeutics, to fund development and advance candidates through clinical milestones.
- Vepdegestrant Phase 3 breast cancer data approaches
- Pfizer and Bayer milestone payments offset cash burn
- PROTAC pipeline expansion raises operating expense outlook
| Net Income: -221.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA -14.42 > 1.0 |
| NWC/Revenue: 575.8% < 20% (prev 179.4%; Δ 396.5% < -1%) |
| CFO/TA -0.39 > 3% & CFO -254.1m > Net Income -221.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.0m) vs 12m ago -11.97% < -2% |
| Gross Margin: 94.18% > 18% (prev 98.45%; Δ -4.27% > 0.5%) |
| Asset Turnover: 10.85% > 50% (prev 42.64%; Δ -31.80% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.80 (Total Current Assets 630.7m - Total Current Liabilities 115.9m) / Total Assets 647.5m |
| B: -2.58 (Retained Earnings -1.67b / Total Assets 647.5m) |
| C: -0.27 (EBIT TTM -221.0m / Avg Total Assets 824.3m) |
| D: 1.48 (Book Value of Equity 386.8m / Total Liabilities 260.7m) |
| Altman-Z'' = -3.44 = D |
| DSRI: 3.0 (Receivables 6.40m/8.40m, Revenue 89.4m/426.9m) |
| GMI: 1.05 (GM 98.45% / 94.18%) |
| AQI: 1.13 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 0.21 (Revenue 89.4m / 426.9m) |
| TATA: 0.05 (NI -221.3m - CFO -254.1m) / TA 647.5m) |
| Beneish M = -1.82 (Cap -4..+1) = B |
As of July 08, 2026, the stock is trading at USD 8.59 with a total of 844,416 shares traded. Over the past week, the price has changed by +3.62%, over one month by +20.14%, over three months by -24.45% and over the past year by +10.27%.
Current recommended Stop Loss: 7.70 (which is 10.4% or 2 ATR below the current price).
Arvinas has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy ARVN.
- StrongBuy: 9
- Buy: 4
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.8 | 72.3% |
P/E Forward = 17.8571
P/S = 6.0552
P/B = 1.3678
Revenue TTM = 89.4m USD
EBIT TTM = -221.0m USD
EBITDA TTM = -216.5m USD
Long Term Debt = 300k USD (from longTermDebt, last quarter)
Short Term Debt = 2.00m USD (from shortTermDebt, last quarter)
Debt = 16.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.10m
Net Debt = -598.2m USD (calculated: Debt 16.7m - CCE 614.9m)
Enterprise Value = 541.3m USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = unknown (Ebit TTM -221.0m / Interest Expense TTM 0.0)
EV/FCF = -2.11x (Enterprise Value 541.3m / FCF TTM -256.9m)
FCF Yield = -47.46% (FCF TTM -256.9m / Enterprise Value 541.3m)
FCF Margin = -287.4% (FCF TTM -256.9m / Revenue TTM 89.4m)
Net Margin = -247.5% (Net Income TTM -221.3m / Revenue TTM 89.4m)
Gross Margin = 94.18% ((Revenue TTM 89.4m - Cost of Revenue TTM 5.20m) / Revenue TTM)
Gross Margin QoQ = 92.95% (prev 87.37%)
Tobins Q-Ratio = 0.84 (Enterprise Value 541.3m / Total Assets 647.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 16.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -174.6m (EBIT -221.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.44 (Total Current Assets 630.7m / Total Current Liabilities 115.9m)
Debt / Equity = 0.04 (Debt 16.7m / totalStockholderEquity, last quarter 386.8m)
Debt / EBITDA = 2.76 (negative EBITDA) (Net Debt -598.2m / EBITDA -216.5m)
Debt / FCF = 2.33 (negative FCF - burning cash) (Net Debt -598.2m / FCF TTM -256.9m)
Total Stockholder Equity = 498.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.85% (Net Income -221.3m / Total Assets 647.5m)
RoE = -44.39% (Net Income TTM -221.3m / Total Stockholder Equity 498.6m)
RoCE = -44.30% (EBIT -221.0m / Capital Employed (Equity 498.6m + L.T.Debt 300k))
RoIC = -33.00% (negative operating profit) (NOPAT -174.6m / Invested Capital 529.1m)
WACC = 11.21% (E(541.3m)/V(558.0m) * Re(11.56%) + D(16.7m)/V(558.0m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 26.97 | Cagr: 2.08%
[DCF] Fair Price = unknown (Cash Flow -256.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: 42.48 | Revenue CAGR: 34.50% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.27 | Chg30d=+18.40% | Revisions=+40% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.83 | Chg30d=-0.31% | Revisions=+27% | Analysts=13
EPS current Year (2026-12-31): EPS=-2.86 | Chg30d=+1.13% | Revisions=+40% | GrowthEPS=-151.2% | GrowthRev=-51.5%
EPS next Year (2027-12-31): EPS=-3.45 | Chg30d=-3.60% | Revisions=+7% | GrowthEPS=-20.4% | GrowthRev=-46.3%
[Analyst] Revisions Ratio: +34% (up=32, down=15)